Long-term study of levodopa gel for advanced Parkinson's
Part of Brain & nervous system clinical trials.
This trial tests how well a levodopa-entacapone-carbidopa intestinal gel works over time for people with advanced Parkinson's disease who have severe motor fluctuations and dyskinesia. It's for those who've already used a similar treatment (foslevodopa) for at least a month and whose doctor decided to start this gel.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with advanced Parkinson's disease.
- You have severe motor fluctuations (on-off periods) and dyskinesia (involuntary movements).
- Your doctor has decided to start you on the study gel (LECIGON®).
- You have used a similar treatment (foslevodopa given under the skin) for at least one month.
- You or your legal guardian agree to the study and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gel form of levodopa (called Lecigon) given through a tube into the intestine to see if it helps reduce mood swings, impulsive behaviors, and other mental side effects in people with Parkinson's who already have motor fluctuations. It is for people who have had Parkinson's for at least 5 years and are between 18 and 75 years old.
This study looks at a new pump treatment (foslevodopa/foscarbidopa) for people with advanced Parkinson's who are having motor fluctuations. It aims to see if it improves quality of life when started earlier in the advanced stage.
This study is looking at how a new continuous 24-hour injection treatment (foslevodopa/foscarbidopa) affects quality of life in people with advanced Parkinson's disease. It is a real-world study, meaning you just take the medication as your doctor prescribes, and researchers observe the results.
This study looks at how well a treatment called foslevodopa/foscarbidopa works for people with advanced Parkinson's disease. It is given as a shot under the skin (subcutaneous) and is already being used in clinics. The study will follow people who are already starting this treatment as part of their regular care.
This study tests a new pump-delivered combination of Parkinson's medications (foslevodopa/foscarbidopa) in adults who have recently started having motor fluctuations but are not yet using other device therapies. It aims to see how well it works in real life and may offer better symptom control.
This study looks at how a Parkinson's drug delivered under the skin (foslevodopa/foscarbidopa) affects sleep problems in people with advanced Parkinson's. It is a real-world study that follows your usual treatment, no new experimental drug is being tested.
Hear when a new Advanced Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.